Literature DB >> 30959462

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

Al B Benson1, Michael I D'Angelica2, Daniel E Abbott3, Thomas A Abrams4, Steven R Alberts5, Daniel A Anaya6, Robert Anders7, Chandrakanth Are8, Daniel Brown9, Daniel T Chang10, Jordan Cloyd11, Anne M Covey2, William Hawkins12, Renuka Iyer13, Rojymon Jacob14, Andreas Karachristos15, R Kate Kelley16, Robin Kim17, Manisha Palta18, James O Park19, Vaibhav Sahai20, Tracey Schefter21, Jason K Sicklick22, Gagandeep Singh23, Davendra Sohal24, Stacey Stein25, G Gary Tian26, Jean-Nicolas Vauthey27, Alan P Venook16, Lydia J Hammond28, Susan D Darlow28.   

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.

Entities:  

Year:  2019        PMID： 30959462     DOI： 10.6004/jnccn.2019.0019

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  73 in total

Review 1.  Interventional Oncology Approach to Hepatic Metastases.

Authors:  Cathal O'Leary; Michael C Soulen; Susan Shamimi-Noori
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

2.  Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation.

Authors:  Jonathan Tefera; Margarita Revzin; Julius Chapiro; Lynn Jeanette Savic; David Mulligan; Ramesh Batra; Tamar Taddei; Dhanpat Jain; Xuchen Zhang
Journal:  J Clin Pathol       Date:  2020-05-19       Impact factor: 3.411

3.  YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling.

Authors:  Chengjie Mei; Xiang Jiang; Yang Gu; Xiaoling Wu; Weijie Ma; Xi Chen; Ganggang Wang; Ye Yao; Yingyi Liu; Zhonglin Zhang; Yufeng Yuan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 4.  Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.

Authors:  S Bennett; K Søreide; S Gholami; P Pessaux; C Teh; E Segelov; H Kennecke; H Prenen; S Myrehaug; D Callegaro; J Hallet
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

5.  Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein.

Authors:  Rui Wang; Zhijian Xu; Jiaping Tian; Qian Liu; Jingwen Dong; Lijuan Guo; Boning Hai; Xia Liu; Hangping Yao; Zhi Chen; Junjie Xu; Lijun Zhu; Haiyi Chen; Tingjun Hou; Weiliang Zhu; Jimin Shao
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry.

Authors:  Daniel Brown; Henry Krebs; Jayson Brower; Ryan O'Hara; Eric Wang; Kirubahara Vaheesan; Liping Du; Lea Matsuoka; Donna D'Souza; Daniel Y Sze; Jafar Golzarian; Ripal Gandhi; Andrew Kennedy
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Describing Treatment Patterns for Elderly Patients with Intrahepatic Cholangiocarcinoma and Predicting Prognosis by a Validated Model: A Population-Based Study.

Authors:  Hanlong Zhu; Kun Ji; Wei Wu; Si Zhao; Jian Zhou; Chunmei Zhang; Ruiyi Tang; Lin Miao
Journal:  J Cancer       Date:  2021-03-30       Impact factor: 4.207

8.  Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.

Authors:  Xu Yang; Ying Hu; Keyan Yang; Dongxu Wang; Jianzhen Lin; Junyu Long; Fucun Xie; Jinzhu Mao; Jin Bian; Mei Guan; Jie Pan; Li Huo; Ke Hu; Xiaobo Yang; Yilei Mao; Xinting Sang; Jiao Zhang; Xi Wang; Henghui Zhang; Haitao Zhao
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 9.  Management of Intrahepatic Cholangiocarcinoma.

Authors:  Sudha Kodali; Akshay Shetty; Soumya Shekhar; David W Victor; Rafik M Ghobrial
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

Review 10.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.